open access

Vol 20, No 2 (2015)
Original research articles
Published online: 2015-03-01
Submitted: 2014-06-30
Get Citation

Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules

Sara Di Santo, Marianna Trignani, Matteo Neri, Angelo Milano, Paolo Innocenti, Maria Taraborrelli, Antonietta Augurio, Annamaria Vinciguerra, Monica Di Tommaso, Lucia Anna Ursini, Angelo Di Pilla, Marta Di Nicola, Domenico Genovesi
DOI: 10.1016/j.rpor.2014.11.001
·
Rep Pract Oncol Radiother 2015;20(2):128-134.

open access

Vol 20, No 2 (2015)
Original research articles
Published online: 2015-03-01
Submitted: 2014-06-30

Abstract

Aim

Main endpoint was a response rate to therapy; secondary endpoints were disease-free survival, overall survival, acute and late toxicities, specially in terms of anorectal and urinary continence.

Background

Radiochemotherapy for anal cancer achieves a good clinical response, locoregional control, anal function preservation. However, oncologic outcomes can differ using radiotherapy plus fluorouracil and mytomicin vs. cisplatin and fluorouracil.

Methods

Between 2000 and 2012, 27 anal cancer patients receiving radiotherapy combined with two different radiochemotherapy schedules, fluorouracil and mytomicin (group A) and cisplatin plus fluorouracil (group B). The Kaplan–Meier method was also used to estimate local control, overall survival and disease free survival. Statistical significance between curves was evaluated using the Log-rank test.

Results

Complete pathological response was found in 85.2% of patients, with higher rates of response in the group A (100% vs. 63.6%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.039). No significantly difference was found between the two groups for the other endpoints. Low rates of both acute and late toxicities were recorded.

Conclusion

Radiotherapy plus fluorouracil and mytomicin provide a better complete pathological response than radiotherapy plus cisplatin and fluorouracil and a greater rate of anal sphincter function preservation. Globally, radiochemotherapy of the anal cancer provides excellent clinical outcomes with a good profile of acute and late toxicity, without difference between the two groups studied.

Abstract

Aim

Main endpoint was a response rate to therapy; secondary endpoints were disease-free survival, overall survival, acute and late toxicities, specially in terms of anorectal and urinary continence.

Background

Radiochemotherapy for anal cancer achieves a good clinical response, locoregional control, anal function preservation. However, oncologic outcomes can differ using radiotherapy plus fluorouracil and mytomicin vs. cisplatin and fluorouracil.

Methods

Between 2000 and 2012, 27 anal cancer patients receiving radiotherapy combined with two different radiochemotherapy schedules, fluorouracil and mytomicin (group A) and cisplatin plus fluorouracil (group B). The Kaplan–Meier method was also used to estimate local control, overall survival and disease free survival. Statistical significance between curves was evaluated using the Log-rank test.

Results

Complete pathological response was found in 85.2% of patients, with higher rates of response in the group A (100% vs. 63.6%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.039). No significantly difference was found between the two groups for the other endpoints. Low rates of both acute and late toxicities were recorded.

Conclusion

Radiotherapy plus fluorouracil and mytomicin provide a better complete pathological response than radiotherapy plus cisplatin and fluorouracil and a greater rate of anal sphincter function preservation. Globally, radiochemotherapy of the anal cancer provides excellent clinical outcomes with a good profile of acute and late toxicity, without difference between the two groups studied.

Get Citation

Keywords

Anal cancer; Radiotherapy; Complete clinical response; FUMIR; PLAFUR

About this article
Title

Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 2 (2015)

Pages

128-134

Published online

2015-03-01

DOI

10.1016/j.rpor.2014.11.001

Bibliographic record

Rep Pract Oncol Radiother 2015;20(2):128-134.

Keywords

Anal cancer
Radiotherapy
Complete clinical response
FUMIR
PLAFUR

Authors

Sara Di Santo
Marianna Trignani
Matteo Neri
Angelo Milano
Paolo Innocenti
Maria Taraborrelli
Antonietta Augurio
Annamaria Vinciguerra
Monica Di Tommaso
Lucia Anna Ursini
Angelo Di Pilla
Marta Di Nicola
Domenico Genovesi

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl